Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
This notice from the Korea Exchange announces that Samsung Biologics’ sub-class industry designation has been revised to ‘Manufacture of Basic Pharmaceutical Products’ due to amendments in standard classification regulations.
📊 [Key Disclosure Details & Summary Statistics]
- Title: Notice of Industry Reclassification
- Company Name: Samsung Biologics Co., Ltd.
- Industry & Code Before Change:
- (Section) Manufacturing (03)
- (Division) Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (21)
- (Group) Manufacture of Basic Pharmaceutical Products and Biological Preparations (01)
- Industry & Code After Change:
- (Section) Manufacturing (03)
- (Division) Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (21)
- (Group) Manufacture of Basic Pharmaceutical Products (01)
- Effective Date: July 1, 2024
- Reason for Change: Amendment to the Korea Standard Industrial Classification (KSIC) and Enforcement Rules of the KOSPI Market Listing Regulations
- Regulatory Basis: Article 132 of the Enforcement Rules of the KOSPI Market Listing Regulations (Korea Exchange)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Reclassification Updates in Subsequent Periodic Reports
This disclosure serves as an administrative update reflecting regulatory changes made by Statistics Korea and the Korea Exchange. Reviewing whether the updated sub-class industry designation is accurately reflected in official company documents following the effective date is important for verifying the company’s official regulatory classification. Related details can be confirmed in future filings such as Quarterly, Half-Yearly, or Annual Reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
